Table 2. Proportion of Patients Reaching a Threshold of VAT <140 cm2 by Treatment and BMI Category.
| Baseline VAT (cm 2 ) | |||||||
| n (%) | Placebo (N = 263) | Tesamorelin (N = 543) | |||||
| Week 26 VAT (cm 2 ) a | <140 | ≥140 | <140 | ≥140 | |||
| <140 | 86 (86.0%) | 14 (8.6%) | 185 (95.9%) | 80 (22.9%) | |||
| <140 | 140 to <200 | ≥200 | <140 | 140 to <200 | ≥200 | ||
| <140 | 86 (86.0%) | 12 (17.4%) | 2 (2.1%) | 185 (95.9%) | 65 (44.2%) | 15 (7.4%) | |
| 140 to <200 | 12 (12.0%) | 44 (63.8%) | 13 (13.8%) | 7 (3.6%) | 70 (47.6%) | 55 (27.1%) | |
| ≥200 | 2 (2.0%) | 13 (18.8%) | 79 (84.0%) | 1 (0.5%) | 12 (8.2%) | 133 (65.5%) | |
| Total | 100 | 69 | 94 | 193 | 147 | 203 | |
| Baseline VAT (cm 2 ) | |||||||
| n/N (%) | Placebo (N = 263) | Tesamorelin (N = 543) | |||||
| Week 26 VAT (cm 2 ) | BMI Category (kg/m 2 ) | <140 | ≥140 | <140 | ≥140 | ||
| <140 | Normal (18.5 to <25) | 20/24 (83.3%) | 1/19 (5.3%) | 33/35 (94.3%) | 11/45 (24.4%) | ||
| Overweight (25 to <30) | 40/48 (83.3%) | 9/85 (10.6%) | 98/101 (97.0%) | 49/169 (29.0%) | |||
| Obese (≥30) | 26/28 (92.9%) | 4/59 (6.8%) | 54/57 (94.7%) | 20/136 (14.7%) | |||
Abbreviations: BMI, body mass index; VAT; visceral adipose tissue.
a Statistically significant difference in the pattern of change in VAT for patients on tesamorelin treatment vs. placebo (p<0.0001 from exact likelihood ratio test of association).